

Product Data Sheet

Cas No.:	136381-85-6	Cat. No:	PC11209				
Product Name:	SR 27897						
Product synonym:	2-[[[4-(2-氯苯基)-2-噻唑基]氨基]羰基]-1H-吲哚-1-乙酸						
Chemical name:	SR 27897						
MF:	C20H14N3O3SCL FW: 411.86146						
Purity:	≥98%	Batch No.:	-				
Storage:							
Structural formula:	OH CI						
λmax:	-	Formulation:	-				
Solubility :							
SMILES:	ClC1C=CC=CC=1C1=CSC(NC(C2=CC3C(=CC=CC=3)N2CC(O)=O)=O)=N1						
InChI Code:		-					
InChl Key:							
	WARNING This product is not for human or veterinary use.						

Product Description

CCK1受体拮抗剂,Lintitript (SR 27897) 是一种高效,选择性,口服活性,竞争性和非肽类 CCK1 受体拮抗剂,EC50 为 6 nM,Ki 为 0.2 nM。Lintitript 对 CCK1 的选择性比对 CCK2 受体的选择性高 33 倍以上 (EC50值为 200 nM)

生物活性	Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC_{50} of 6 nM and a K_i of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC_{50} value of 200 nM). Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin.
IC50 & Target[1][2]	EC50: 6 nM (cholecystokinin (CCK1) receptor); Ki: 0.2 nM (cholecystokinin (CCK1) receptor)

体外研究(In Vitro)	体外研究, Lintitript (SI	体外研究, Lintitript (SR 27897) is a competitive antagonist of cholecystokinin (CCK)-stimulated amylase release in isolated rat						
	pancreatic acini (pA $_2$ = 7.50) and of CCK-induced guinea pig gall bladder contractions (pA $_2$ = 9.57).							
	Lintitript produces concentration dependent inhibition of [I]CCK binding to CCK1 receptor sites in the rat pancreas (IC ₅₀ value of							
	0.58 nM) and also to CCK 2 sites in the guinea pig cortex (IC ₂ value of 479 nM). Lintitript inhibits [I]gastrin binding to gastrin							
	receptors. Lintitript (0.	receptors. Lintitript (0.5 nM) increases the dissociation constant of CCK for the CCK A receptor ($K_d = 1.8 \text{ to } 7.2 \text{ nM}$) without						
	modifying the maximum number of receptors ($B_{max} = 1800 \text{ to } 1770 \text{ fmol/mg}$).							
	Medlife has not independently confirmed the accuracy of these methods. They are for reference only.							
体内研究(In Vivo) 包装储存	Lintitript (SR 27897; 1 i	Lintitript (SR 27897; 1 mg/kg, i.v.) completely reverses the CCK-induced amylase secretion. Lintitript also inhibits CCK-induced						
	gastric and gallbladder	gastric and gallbladder emptying in mice (ED $_{50}$ s = 3 and 72 μ g/kg, respectively). Lintitript is also very active (ED $_{50}$ = 27 μ g/kg						
	p.o.) in the gall bladder	p.o.) in the gall bladder emptying protocol with egg yolk as an inducer of endogenous CCK release.						
	Medlife has not independently confirmed the accuracy of these methods. They are for reference only.							
	Powder -20°C 3	years						
	4°C 2	years						
	In solvent -80°C 6	months						
	-20°C ₁	month						
	体外研究:	体外研究:						
溶解度数据	DMSO: 100 mg/mL (242.80 mM; Need ultrasonic)							
		溶剂体积 质量 浓度	1 mg	5 mg	10 mg			
	配制储备溶液	1 mM	2.4280 mL	12.1400 mL	24.2801 mL			
		5 mM	0.4856 mL	2.4280 mL	4.8560 mL			
		10 mM	0.2428 mL	1.2140 mL	2.4280 mL			
	冻融造成的产品。	式和期限: -80°C, 6 months; -20°						